Shanghai Fosun Pharmaceutical's (SHA:600196, HKG:2196) unit, Fosun Pharma (Xuzhou), received approval from the National Medical Products Administration for the registration of venlafaxine hydrochloride extended-release tablets, according to a Shanghai bourse filing on Saturday.
The pharmaceutical company's Shanghai shares rose less than 1% during Monday's morning trade.
The drug is used to treat depression and generalized anxiety disorder.